Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.

Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.

FRISCO, Texas, June 24, 2022 – PRNewswire Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in the Journal of Clinical Investigation1 led by researchers at The University of Texas MD Anderson Cancer Center demonstrating that SIK2...